Precision
Exceptionally uniform particles, with ±3% size variation.
The product
EncapX®
The first patented continuous nanoliposome production system based on supercritical CO₂
Continuous supercritical CO₂ encapsulation system
>97%
encapsulation efficiency
±3%
size variation
35 °C
process temperature
- Continuousno batch-to-batch drift
- Clog-freemillifluidic channels
- GMP-compatible designpressure, temperature, flow control
EncapX® is an automated, continuous supercritical CO₂ platform for the reproducible and scalable production of nanoliposomes and lipid nanoparticles encapsulating your active ingredients. A patented millifluidic process gives precise control of particle formation, reduces solvent use and eliminates clogging. It serves R&D, preclinical development and industrial manufacturing, with a design compatible with GMP environments.
Whatever the target scale, EncapX® forms the same particles: industrial scale is reached by multiplying the same device, not by redeveloping the process.
Key benefits
Built for quality at every scale
Efficiency
Over 97% encapsulation efficiency.
Continuous
No clogging, automated production and low operating costs.
Gentle
Runs at 35 °C, preserving heat-sensitive actives such as enzymes, probiotics and mRNA.
Clean
No toxic solvents, no residues, no harmful emissions.
Scalable
The same process from R&D to industrial scale, with a GMP-compatible design.
Low maintenance
No chip or cartridge to replace, and little maintenance. Microfluidic equipment relies on parts that clog and must be changed.
Performance
A measurable advantage over conventional methods
EncapX® against microfluidics and thin-film hydration, on level of control and scalability.
5-10×
process time reduced
2-4×
operating cost reduced
~1,000×
wider channels than microfluidic ones
Measured, not promised
Recent DLS characterisation of nanoliposomes produced with EncapX®: main intensity peak at 93.3 nm, PDI 0.151, a single unimodal population with no detectable secondary peak. A PDI around 0.15 indicates a narrow size distribution, critical for reproducibility, colloidal stability and predictable biological performance.
Technical specifications
What the system delivers
| Particle size range | ~60-150 nm (application-dependent) |
|---|---|
| Size distribution | Narrow (±3%) |
| Carriers | Liposomes, lipid nanoparticles (LNPs) |
| Compatible actives | RNA, mRNA, siRNA, antisense RNA, proteins, antibodies, peptides, small molecules, vitamins, plant extracts |
| Operating mode | Continuous |
| Automation | Fully automated |
| Control parameters | Pressure, temperature, flow rates |
| Process temperature | 35 °C |
| Channels | Millifluidic (mm scale), clog-free |
| Scale | R&D to industrial, GMP-compatible design |
Need the full datasheet?
Request the technical datasheet and we will send the detailed specification pack.
Scientific evidence
Peer-reviewed results you can check
- 2023
Supercritical millifluidic process for siRNA encapsulation in nanoliposomes
Journal of Drug Delivery Science and Technology · 87, 104804
- 2024
Supercritical millifluidic process for lipid-based formulations of anti-cancer drugs
20th European Meeting on Supercritical Fluids · Maribor
From test to production
An offer for every stage
01 · Screening
Your active ingredient, encapsulated on EncapX® in our Marseille lab.
Feasibility & formulation study
02 · Development
Process optimisation for your product and target scale.
Formulation and process development
03 · Scale-up
Pilot and demonstration batches, depending on project scope.
Pilot batches
04 · Manufacturing
Design, sale, installation, training and technical support.
EncapX® system on your site
Let's talk
Ready to test your active ingredient?
Book a technical call or request a feasibility study on EncapX®